Trial Profile
A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Entinostat (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ENCORE 601; KEYNOTE 142
- Sponsors Syndax Pharmaceuticals
- 06 Sep 2023 Status changed from active, no longer recruiting to completed.
- 22 Jun 2023 Planned End Date changed from 1 May 2023 to 1 Jul 2023.
- 10 Mar 2023 Planned End Date changed from 30 Sep 2022 to 1 May 2023.